Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma
Authors
- Yinqiang Zhang (ORCID: https://orcid.org/0000-0002-5423-1774)
- Qiaolin Liu
- Heng Mei (ORCID: https://orcid.org/0000-0001-7941-2443)
- Li Su (ORCID: https://orcid.org/0000-0002-6347-3986)
- Lin Liu (ORCID: https://orcid.org/0000-0001-9690-1302)
- Wei Xie (ORCID: https://orcid.org/0000-0002-4358-3950)
Institutions
- Union Hospital (HK)
- Shanghai Cell Therapy Research Institute (CN)
- Huazhong University of Science and Technology (CN)